Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Julphar
McKinsey
Merck
Boehringer Ingelheim
Dow
Cerilliant
US Army
Daiichi Sankyo

Generated: November 21, 2018

DrugPatentWatch Database Preview

Duvelisib - Generic Drug Details

« Back to Dashboard

What are the generic sources for duvelisib and what is the scope of duvelisib freedom to operate?

Duvelisib is the generic ingredient in one branded drug marketed by Verastem Inc and is included in one NDA. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for duvelisib
US Patents:0
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 50
Clinical Trials: 19
Patent Applications: 106
DailyMed Link:duvelisib at DailyMed
Synonyms for duvelisib
(S)-3-(1-((9H-Purin-6-yl)amino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one
(S)-3-(1-(7H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one
(S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one
1(2H)-Isoquinolinone, 8-chloro-2-phenyl-3-((1S)-1-(9H-purin-6-ylamino)ethyl)-
1201438-56-3
610V23S0JI
8-Chloro-2-phenyl-3-((1S)-1-(7H-purin-6-ylamino)ethyl)isoquinolin-1(2H)-one
AB0032504
AC-30239
AJ-128213
AK145604
AKOS022186370
AOB87713
AS-16309
AX8268013
BC600328
BCP07042
BDBM50193013
CHEBI:131169
CHEMBL3039502
compound 4904 [Patent US8193182]
CS-0888
D0RU0O
D10555
DB11952
DTXSID80152697
Duvelisib (IPI-145 INK1197)
Duvelisib (IPI-145, INK1197)
Duvelisib (USAN/INN)
Duvelisib [USAN:INN]
EX-A1562
GTPL7795
HY-17044
IN2292
INK-1147
INK-1197
INK-1197|||IPI-145|||8-Chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]isoquinolin-1-one
INK1197
IPI 145
IPI-145
IPI-145 (INK1197)
IPI-145 pound>>Duvelisib
IPI-145, INK 1197, Duvelisib
IPI145
KB-77917
KS-0000062P
MolPort-028-600-025
MolPort-044-561-365
NCGC00351482-01
QC-10232
s7028
SCHEMBL153543
SCHEMBL18343557
SCHEMBL19670020
SJVQHLPISAIATJ-ZDUSSCGKSA-N
ST24036081
SYN1175
UNII-610V23S0JI
W-5592
X5816
ZINC88346058

US Patents and Regulatory Information for duvelisib

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Verastem Inc COPIKTRA duvelisib CAPSULE;ORAL 211155-001 Sep 24, 2018 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Verastem Inc COPIKTRA duvelisib CAPSULE;ORAL 211155-002 Sep 24, 2018 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Julphar
McKinsey
Merck
Boehringer Ingelheim
Dow
Cerilliant
US Army
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.